Key Points GAAP revenue surged to $66.8 million in Q2 2025, driven by recognition of one-time license and milestone payments, exceeding analyst estimates by 3,065.9% (GAAP). GAAP loss per share ...

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ...

US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the ...

Early symptoms like fatigue, breathlessness, swelling mimic common heart issues, causing cardiac amyloidosis to go undetected ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

An anti-hazing network honors a UVA leader, the American Heart Association lauds UVA Health for heart and stroke care, and ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...

Are men’s and women’s hearts that different? Yes, they are, and knowing those differences could save a woman’s life.

The venture capital arms of Pittsburgh-based UPMC and UChicago Medicine have invested in a healthcare AI startup as part of a $55 million series C funding round. UPMC Enterprises and UCM Ventures ...